Drugs / GSK356278
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01573819 | Nov 2011 → Apr 2012 | Huntington disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01602900 | Nov 2011 → Apr 2012 | Huntington disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01031186 | Nov 2009 → Apr 2010 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK356278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01602900 ↗ |
| Known as | GSK356278B | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297384 ↗ |
| Action | Inhibit | “GSK356278 (PDE4 Inhibitor)” NCT01031186 ↗ |
| Modality | Small molecule | — CHEMBL4297384 ↗ |
| Route | Oral | “GSK356278 tablets behave in the body after it is swallowed” NCT01573819 ↗ |